This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Smith, P. F Articles by Darlington, C. L Search for Related Content PubMed PubMed Citation Articles by Smith, P. F Articles by Darlington, C. L Social Bookmarking                   What's this?

Recent developments in drug therapy for multiple sclerosis

Department of Pharmacology, School of Medical Sciences, University of Otago Medical School, Dunedin, New Zealand

Cynthia L Darlington

Department of Psychology and the Neuroscience Research Centre, University of Otago, Dunedin, New Zealand

Symptomatic treatment of multiple sclerosis (MS) includes a diverse range of drugs intended to relieve the specific symptoms with which a patient may present at a particular point in the progression of the disease. These drugs, not specifically designed for the treatment of MS, may include antispastic agents (e.g. baclofen), drugs to reduce tremor (e.g. clonazepam), anticholinergics (e.g. oxybutynin) which relieve urinary symptoms, anti- epileptics (e.g. carbamazepine) to control neuralgia, stimulants to reduce fatigue (e.g. amantadine), and antidepressants (e.g. fluoxetine) to treat depression. The treatment of acute relapses or exacerbations is dominated by corticosteroids such as methylprednisolone. The most active area of current investigation is the development of drugs which will inhibit the progression of the disease process itself, and in this category the beta- and alpha-interferons are the most effective drugs currently available, although many new treatments are currently in trials, including immunoglobulin, copolymer-1, bovine myelin, T-cell receptor (TCR) peptide vaccines, platelet-activating factor (PAF) antagonists, matrix metallo-proteinase inhibitors, campath-1, and insulin-like growth factor (IGF).

Key Words: multiple sclerosis • drug therapy • beta-interferon

Multiple Sclerosis, Vol. 5, No. 2, 110-120 (1999)
DOI: 10.1177/135245859900500208


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A Diamond and J Jankovic The effect of deep brain stimulation on quality of life in movement disorders J. Neurol. Neurosurg. Psychiatry, September 1, 2005; 76(9): 1188 - 1193. [Abstract] [Full Text] [PDF]